Olink Holding AB (publ)(OLK) Stock Research - Grey Stern Research

Olink Holding AB (publ) (OLK) Stock Analysis

$26.08 (0.31%)

OLK Financial Performance


Use the table below to view Olink Holding AB (publ)'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $26.08 -
52 Week Low $14.10 -
52 Week High $26.09 -
Market Cap $3.2 Billion 3/14
Gross Margin 61% 6/14
Profit Margin -56% 9/14
EBITDA margin -73% 9/14
Q1 - 2024 Revenue $28.6 Million 7/14
Q1 - 2024 Earnings -$16.0 Million 12/14
Q1 - 2024 Free Cash Flow -$8.2 Million 10/14
Trailing 4 Quarters Revenue $171.4 Million 6/14
Trailing 4 Quarters Earnings -$33.7 Million 10/14
Quarterly Earnings Growth -14% 10/14
Annual Earnings Growth -1544% 14/14
Quarterly Revenue Growth 4% 5/14
Annual Revenue Growth -15% 12/14
Cash On Hand $109.3 Million 4/14
Short Term Debt $4.1 Million 8/14
Long Term Debt $22.1 Million 8/14

Olink Holding AB (publ) Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Olink Holding AB (publ)'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 5/14
PS 18.91 2/14
PB 7.03 1/14
PC 29.67 3/14
Liabilities to Equity 0.18 11/14
ROA -0.06 6/14
ROE -0.07 6/14
Current Ratio 6.68 2/14
Quick Ratio 1.34 5/14
Long Term Debt to Equity 0.05 10/14
Debt to Equity 0.06 9/14
Burn Rate 6.11 4/14
Cash to Cap 0.03 9/14
CCR 0.52 6/14
EV to EBITDA -151.26 14/14
EV to Revenue 18.43 2/14

Company Details

Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.

CEO: Mr. Jon Heimer

Website: https://www.olink.com

Address: Uppsala Science Park Uppsala,

Exchange: NASDAQ Global Market

Industry: Diagnostics & Research

Olink Holding AB (publ) Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Olink Holding AB (publ). If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Syneos Health, Inc. SYNH $4.5 Billion
Qiagen N.V. QGEN $9.6 Billion
Aclaris Therapeutics, Inc. ACRS $274.7 Million
FONAR Corporation FONR $100.9 Million
Neogen Corporation NEOG $2.9 Billion
DarioHealth Corp. DRIO $25.6 Million
Psychemedics Corporation PMD $14.1 Million
Castle Biosciences, Inc. CSTL $862.1 Million
Neuronetics, Inc. STIM $34.9 Million
Exagen Inc. XGN $82.9 Million
Burning Rock Biotech Limited BNR $62.5 Million
Sera Prognostics, Inc. SERA $210.6 Million
LumiraDx Limited LMDX $0
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
OLK Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 28.6 Million -$16.0 Million
Q4 2023 $ 69.3 Million -$7.6 Million
Q3 2023 $ 44.2 Million -$1.8 Million
Q2 2023 $ 29.4 Million -$8.3 Million
Q1 2023 $ 27.5 Million -$14.0 Million
Q4 2022 $ 57.9 Million $5.4 Million
Q3 2022 $ 31.8 Million -$1.3 Million
Q2 2022 $ 27.5 Million -$4.8 Million

View All

OLK Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $109.3 Million $542.9 Million $26.2 Million $461.6 Million
Q4 2023 $121.0 Million $602.3 Million $26.8 Million $502.7 Million
Q3 2023 $130.3 Million $552.8 Million $25.5 Million $472.1 Million
Q2 2023 $151.2 Million $530.5 Million $8.2 Million $470.5 Million
Q1 2023 $172.6 Million $559.9 Million $9.0 Million $498.0 Million
Q4 2022 $75.1 Million $476.3 Million $9.4 Million $410.7 Million
Q3 2022 $77.1 Million $438.2 Million $9.1 Million $378.9 Million
Q2 2022 $99.8 Million $473.2 Million $8.9 Million $410.7 Million

View All

OLK Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 -$8.2 Million -$1.5 Million -$11.7 Million
Q4 2023 -$11.3 Million -$8.3 Million -$9.3 Million
Q3 2023 -$21.9 Million -$6.3 Million -$20.9 Million
Q2 2023 -$20.8 Million -$4.0 Million -$21.4 Million
Q1 2023 $2.6 Million -$2.8 Million $97.5 Million
Q4 2022 -$2.5 Million -$2.4 Million -$2.0 Million
Q3 2022 -$22.2 Million -$2.0 Million -$22.7 Million
Q2 2022 -$18.1 Million -$1.8 Million -$20.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions